SUPN

Companies
NASDAQ
Supernus Pharmaceuticals Inc.
Health Care
Price Chart
Overview

About SUPN

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Market Cap
$1.4B
Volume
17.1M
Avg. Volume
17.1M
P/E Ratio
17.687832
Dividend Yield
0.00%
Employees
665.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Drug Manufacturers - Specialty & Generic
Risk & Correlation Analysis
Market Correlation
0.77
Moderate Correlation
Volatility
Medium (0.39)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for SUPN.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, SUPN shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$1.4B
Volume17.1M
P/E Ratio17.69
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 7, 2025

PortfolioPilot Analysis

Get AI-powered insights on how SUPN fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025